Trial Profile
The development of a novel dual-targeting peptide vaccine therapy in patients with resected pancreatic cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2020
Price :
$35
*
At a glance
- Drugs OCV C01 (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Adenosquamous carcinoma; Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week
- 25 Jan 2020 Primary endpoint (Disease-free survival) has been met presented at the 2020 Gastrointestinal Cancers Symposium
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium